Melody Noel Brown

Array ( [id] => 10722699 [patent_doc_number] => 20160068846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-10 [patent_title] => 'MODULATION OF ANDROGEN RECEPTOR EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/854281 [patent_app_country] => US [patent_app_date] => 2015-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65392 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14854281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10722767 [patent_doc_number] => 20160068914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-10 [patent_title] => 'PLASMA CELL DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/851539 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11087 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14851539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10671192 [patent_doc_number] => 20160017338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT' [patent_app_type] => utility [patent_app_number] => 14/849777 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 39322 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14849777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10776609 [patent_doc_number] => 20160122765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'QSOX1 AS AN ANTI-NEOPLASTIC DRUG TARGET' [patent_app_type] => utility [patent_app_number] => 14/849013 [patent_app_country] => US [patent_app_date] => 2015-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 22672 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14849013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10721208 [patent_doc_number] => 20160067355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-10 [patent_title] => 'Composition For Delivery Of Genetic Material' [patent_app_type] => utility [patent_app_number] => 14/847853 [patent_app_country] => US [patent_app_date] => 2015-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 12426 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14847853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678364 [patent_doc_number] => 20160024508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'METHOD FOR IDENTIFYING BIOLOGICALLY ACTIVE OLIGONUCLEOTIDES CAPABLE OF MODULATING THE IMMUNE SYSTEM' [patent_app_type] => utility [patent_app_number] => 14/840628 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 12846 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14840628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971475 [patent_doc_number] => 20170275629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/506010 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 58 [patent_no_of_words] => 60888 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15506010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13081715 [patent_doc_number] => 10060921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-28 [patent_title] => Methods of treating transthyretin (TTR) mediated amyloidosis [patent_app_type] => utility [patent_app_number] => 15/507691 [patent_app_country] => US [patent_app_date] => 2015-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11117 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15507691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476415 [patent_doc_number] => 20150361432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/819606 [patent_app_country] => US [patent_app_date] => 2015-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 12767 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14819606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11670331 [patent_doc_number] => 20170159051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'SMALL INTERFERING RNA AND PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING GALECTIN-12 EXPRESSION AND/OR ENHANCING LIPOLYSIS CONTAINING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/322878 [patent_app_country] => US [patent_app_date] => 2015-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10653 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15322878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163755 [patent_doc_number] => 10487359 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Method for diagnosing fibromyalgia using microRNAs [patent_app_type] => utility [patent_app_number] => 15/501097 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 4 [patent_no_of_words] => 13185 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15501097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10428919 [patent_doc_number] => 20150313931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/801366 [patent_app_country] => US [patent_app_date] => 2015-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7889 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14801366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011291 [patent_doc_number] => 20160208245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'RNA/DNA nanoparticle for siRNA target-specific delivery and vehicle including the same' [patent_app_type] => utility [patent_app_number] => 14/754556 [patent_app_country] => US [patent_app_date] => 2015-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 8881 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14754556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12746380 [patent_doc_number] => 20180140627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => OLIGODEOXY NUCLEOTIDE FOR PREPARING DRUGS FOR INHIBITING TUMOR GROWTH AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 15/538288 [patent_app_country] => US [patent_app_date] => 2015-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15538288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11844798 [patent_doc_number] => 09732342 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Segmented micro RNA mimetics' [patent_app_type] => utility [patent_app_number] => 14/747264 [patent_app_country] => US [patent_app_date] => 2015-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 37 [patent_no_of_words] => 45305 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14747264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11319563 [patent_doc_number] => 09518301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-13 [patent_title] => 'Aptamer for detection of alpha-methylacyl-CoA racemase and diagnostic kit thereof' [patent_app_type] => utility [patent_app_number] => 14/742681 [patent_app_country] => US [patent_app_date] => 2015-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 20 [patent_no_of_words] => 6629 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14742681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10399714 [patent_doc_number] => 20150284724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)' [patent_app_type] => utility [patent_app_number] => 14/741164 [patent_app_country] => US [patent_app_date] => 2015-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 39202 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 28 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14741164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309515 [patent_doc_number] => 10519448 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF [patent_app_type] => utility [patent_app_number] => 14/723740 [patent_app_country] => US [patent_app_date] => 2015-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 7 [patent_no_of_words] => 25051 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14723740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10374679 [patent_doc_number] => 20150259685 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'TREATMENT OF UNCOUPLING PROTEIN 2 (UCP2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO UCP2' [patent_app_type] => utility [patent_app_number] => 14/723798 [patent_app_country] => US [patent_app_date] => 2015-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 24845 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14723798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604414 [patent_doc_number] => 20170121715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'A specific oligonucleotide aptamer for the identification of T-2 toxin' [patent_app_type] => utility [patent_app_number] => 14/909743 [patent_app_country] => US [patent_app_date] => 2015-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 2779 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14909743 [rel_patent_id] =>[rel_patent_doc_number] =>)